AI-Powered MRI Tool Earns Landmark FDA Nod for Parkinson's Mimics

GAINESVILLE, FL – April 07, 2026 – The U.S. Food and Drug Administration has granted a first-of-its-kind classification to an artificial intelligence-powered software designed to help doctors diagnose complex Parkinsonian syndromes, a move that signals a new frontier in neurological diagnostics and offers hope for more accurate and timely patient care.

The Gainesville-based innovator, Neuropacs™ Corp., announced that its neuropacs™ software received De Novo classification from the FDA. The device analyzes standard MRI scans to help clinicians distinguish between Parkinson's disease (PD) and its more aggressive mimics, such as multiple system atrophy (MSAp) and progressive supranuclear palsy (PSP). This landmark decision establishes an entirely new regulatory category for a "Parkinsonian syndrome diagnostic aid," paving the way for future innovation in the field.

A New Era for Neurological Diagnostics

The FDA's De Novo pathway is reserved for novel, low-to-moderate risk medical devices that have no existing equivalent on the market. By granting this classification, the agency not only clears neuropacs™ for use but also creates a regulatory benchmark that future devices in this class can follow. This is particularly significant for AI and machine learning (AI/ML) technologies, which are rapidly evolving but have often faced uncertain regulatory pathways.

This approval represents a major step forward in integrating advanced AI into the clinical workflow for neurodegenerative diseases. It addresses a long-standing need for objective, data-driven tools to support what has historically been a subjective diagnostic process.

“neuropacs represents an important step forward in the development of imaging-based tools for neurological evaluation,” said Dr. Martin Handfield, President & CEO of Neuropacs, in a statement. “The FDA’s De Novo classification establishes a new regulatory category for this type of technology and enables broader access to tools that may support clinicians in assessing Parkinsonian syndromes.”

Tackling a Decades-Old Diagnostic Dilemma

For patients experiencing symptoms like tremors, stiffness, and slowed movement, the journey to a correct diagnosis can be long and fraught with uncertainty. Parkinson's disease is the most common diagnosis, but several other conditions—collectively known as atypical Parkinsonian syndromes—present with nearly identical early symptoms. Distinguishing between them is notoriously difficult, yet critically important.

Misdiagnosis rates for Parkinson's disease can be as high as 25-30%, particularly in the initial years. A significant portion of these cases are later revealed to be MSAp or PSP, which have different underlying pathologies, progress more rapidly, and do not respond well to the standard dopamine-replacement therapies used for Parkinson's disease. An accurate diagnosis is essential for setting realistic expectations, developing an appropriate care plan, and enrolling patients in the correct clinical trials for their specific condition.

Currently, diagnosis relies heavily on a neurologist's clinical expertise, observation of symptom progression over time, and a patient's response to medication. While brain imaging is used, visual assessment of standard MRIs often fails to reveal the subtle, microscopic changes that differentiate these diseases in their early stages. A definitive diagnosis has historically only been possible through post-mortem brain tissue analysis.

How AI is Decoding the Brain

The neuropacs™ software aims to overcome these limitations by using AI to see what the human eye cannot. The technology is not a new type of scan but a sophisticated software application that analyzes data from a specific type of scan called diffusion MRI, which is widely available on the 3 Tesla (3T) MRI systems used in most hospitals.

The process begins when a patient undergoes a non-invasive, radiotracer-free diffusion MRI. The scan data is then securely uploaded to the cloud and processed by the neuropacs™ algorithm. This algorithm, built on over 15 years of research and trained on more than 1,000 imaging datasets, analyzes patterns of water molecule movement within the brain tissue. It identifies subtle degenerative patterns characteristic of MSAp and PSP, generating a classification report for the clinician.

This approach was validated in a prospective, multicenter study published in the prestigious journal JAMA Neurology. The study, conducted across 21 leading movement disorder centers, demonstrated the software's high performance in differentiating these syndromes under defined conditions.

It is crucial to note that neuropacs™ is designed as a supplemental aid, not a standalone diagnostic tool. The company emphasizes that the report provides objective, data-driven insights to be interpreted by trained neuroradiologists and neurologists in conjunction with their own clinical evaluation and other diagnostic tests. Patient management decisions are not to be based solely on the software's output, but it provides a powerful new piece of evidence in a complex diagnostic puzzle.

From Research to Reality: The Path to Market

The FDA's green light is the culmination of years of academic research and a strategic business plan. The classification follows closely on the heels of a recently announced $1 million seed funding round for Neuropacs Corp. The investment, led by Neuro Investment Group, LLC, is intended to fuel the company's transition from a research entity to a commercial enterprise, expanding its capacity to support clinical use and research trials.

The software’s compatibility with existing MRI hardware from major manufacturers like Siemens, GE Healthcare, and Philips is a key advantage, potentially lowering the barrier to adoption for hospitals and imaging centers. By integrating into established workflows, the company hopes to make this advanced analysis widely accessible.

The establishment of this new diagnostic category could reshape the competitive landscape for neuroimaging. While other companies are developing AI tools for medical imaging, neuropacs™ has secured a significant first-mover advantage in this specific clinical niche. The regulatory clarity provided by the De Novo classification may also attract further investment and spur development of similar AI-driven tools for other challenging neurological conditions.

For the millions of people affected by Parkinsonism globally, this technological advancement represents a tangible step toward greater diagnostic certainty. By enabling clinicians to make more precise and earlier diagnoses, tools like neuropacs™ have the potential to improve treatment strategies, enhance patient quality of life, and accelerate the development of new therapies for these devastating neurodegenerative diseases.